Latest News for: dosing

Edit

Satellos Announces First Participant Dosed in Phase 2 Pediatric Study of SAT-3247 for Duchenne Muscular Dystrophy

Image Caledonian Record 12 Feb 2026
TORONTO--(BUSINESS WIRE)--Feb 12, 2026-- ....
Edit

Lyell Immunopharma Announces Initiation of Patient Dosing in First-of-Its-Kind Phase 3 Head-To-Head CAR T-Cell Clinical ...

Nasdaq Globe Newswire 12 Feb 2026
LYEL), a clinical-stage company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for ...
Edit

Lyell Immunopharma Announces Initiation of Patient Dosing in First-of-Its-Kind Phase 3

Image Caledonian Record 12 Feb 2026
PiNACLE – H2H will evaluate the efficacy and safety of ...
Edit

Inflexxion Health Expands Access to Customized Low-Dose Testosterone Therapy for Women in the Mountain West

PR Newswire 12 Feb 2026
Yet, despite growing evidence supporting low-dose testosterone therapy for women suffering from low libido and reduced sexual response and satisfaction, access to hormonal care remains limited.
Edit

OU softball pitching staff sure could use good dose of Jen Rocha

The Oklahoman 12 Feb 2026
NORMAN — Patty Gasso heard from Jennifer Rocha soon after the Oklahoma softball team returned from its season-opening weekend in Arizona. Rocha wanted to set up a call with the pitching staff. Gasso tried to knock it down ... It permeates the entire team.
Edit

Iterion Therapeutics Announces First Patient Dosed in Clinical Study of Tegavivint, a First-in-Class Wnt/β-Catenin Inhibitor, ...

Image The Bismarck Tribune 11 Feb 2026
Tegavivint Is the First Wnt/β-Catenin Inhibitor to Demonstrate Tolerability and Monotherapy Clinical Activity in Complex Solid Tumors ... .
Edit

Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002, a Potential Disease-Modifying ...

Business Wire 11 Feb 2026
STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s ...
Edit

iVeena Delivery Systems Announces First Patient Dosed in Phase 1 Study of IVMED-85 in Healthy ...

Image The Joplin Globe 11 Feb 2026
SALT LAKE CITY--(BUSINESS WIRE)--Feb 11, 2026-- ... .
Edit

Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated ...

Nasdaq Globe Newswire 11 Feb 2026
Company Expects to Report Topline Data from OPUS-3 Trial and OPUS-2 Phase 3 Trial Evaluating Concomitant Administration of VAX-31 and a Seasonal Influenza Vaccine in First Half of 2027� ... .
Edit

Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously

Image Hastings Tribune 11 Feb 2026
Company Expects to Report Topline Data from OPUS-3 Trial and OPUS-2 Phase 3 Trial Evaluating Concomitant Administration of VAX-31 and a Seasonal Influenza Vaccine in First Half of 2027 ... .
Edit

SOFIE Biosciences Announces First Patient Dosed in [18F]FAPI-74 Phase 3 Study for Pancreatic Cancer

PR Newswire 11 Feb 2026
First dose at HOAG Health in FAPI-PRO trial for Pancreatic Ductal Adenocarcinoma. A parallel trial focused on gastroesophageal cancers, FAPI-GO, dosed its first patient December 2025 ... The first patient in FAPI-GO was dosed on December 26, 2025.
Edit

Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002, a Potential Disease-Modifying Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA)

Pharmiweb 11 Feb 2026
–Dose-escalating study will evaluate the safety, tolerability and exposure of STK-002 in people with ADOA– ... Secondary objectives are to assess changes in visual function, ocular structure and quality of life after single doses of STK-002.
Edit

Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines (Vaxcyte Inc)

Public Technologies 11 Feb 2026
This Phase 3 study is a randomized, double-blind, active-controlled, descriptive clinical trial designed to evaluate the safety, tolerability and immunogenicity of a single dose of VAX-31 in approximately 720 healthy U.S.
Edit

These running backs could benefit from Ohio State football’s first dose of adversity in 2026

Cleveland 10 Feb 2026
COLUMBUS, Ohio — Ohio State football was given its first dose of adversity for the 2026 season recently ....
Edit

'Fast Reflexes, Laser Focus, a Hefty Dose of Fearlessness': Kart Racer Liam Nachawati Featured in ...

Image The Lufkin News 10 Feb 2026
Media spotlight shines as 2026 race season gets underway ....

Article Search

tools
×
×
×
×